Drugs / PNT100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01191775 | Aug 2010 → Apr 2012 | lymphoma, melanoma, prostate cancer | Sierra Oncology LLC - a GSK company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PNT100 | “PNT2258 is composed of PNT100, a 24-mer oligonucleotide, the active drug substance encapsulated in a liposome.” NCT01191775 ↗ |
| Modality | Oligonucleotide (other) | “PNT2258 is composed of PNT100, a 24-mer oligonucleotide, the active drug substance encapsulated in a liposome.” NCT01191775 ↗ |
| Route | Intravenous | “Patients will receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks).” NCT01191775 ↗ |